General Information of the Compound
| Compound ID |
CP0047409
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
2-[4-[3-[2-(trifluoromethyl)-10-phenothiazinyl]propyl]-1-piperazinyl]ethanol;hydrochloride
Show/Hide
|
||||||||||||||||||
| Synonyms |
Dapotum
10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine
2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol
69-23-8
Anatensol (TN)
Apo-Fluphenazine
Dapotum
Dapotum (TN)
Dapotum D (TN)
Dapotum Injektion (TN)
Decanoate (TN)
Deconoate (TN)
Elinol
Enanthate (TN)
FLUPHENAZINE
Fludecate (TN)
Flufenazin
Flufenazina
Flufenazina [DCIT]
Flunanthate (TN)
Fluorfenazine
Fluorophenazine
Fluorphenazine
Fluphenazine
Fluphenazine (INN)
Fluphenazine [INN:BAN]
Fluphenazine hydrochloride
Fluphenazinum
Fluphenazinum [INN-Latin]
Ftorphenazine
HSDB 3334
Hydrochloride, Fluphenazine
Lyogen (TN)
Modecate (TN)
Moditen (TN)
Moditen (Tabl or elixir)
Moditen Enanthate Injection (TN)
Moditen Hcl
Omca (TN)
Pacinol
Permitil (TN)
Permitil Concentrate
Phthorphenazine
Prolixin
Prolixin (TN)
Prolixin Concentrate
Prolixine
S94
SQ 4918
Sediten (TN)
Selecten (TN)
Sevinol
Sevinol (TN)
Sinqualone (TN)
Siqualine
Siqualon
Trancin (TN)
Triflumethazine
UNII-S79426A41Z
Vespazine
Yespazine
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C22H26F3N3OS
|
||||||||||||||||||
| Molecular Weight |
437.531
|
||||||||||||||||||
| Canonical SMILES |
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
Show/Hide
|
||||||||||||||||||
| InChIKey |
PLDUPXSUYLZYBN-UHFFFAOYSA-N
|
||||||||||||||||||
| CAS |
47646-09-3
69-23-8
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01546, ATP-dependent translocase ABCB1
Protein ID: PT01195, D(1A) dopamine receptor
Protein ID: PT01169, D(1B) dopamine receptor
Protein ID: PT01005, D(2) dopamine receptor
Protein ID: PT00943, D(3) dopamine receptor
Protein ID: PT01206, Histamine H1 receptor
Protein ID: PT01194, Histamine H3 receptor
Protein ID: PT01065, Serine/threonine-protein kinase mTOR
Clinical Information about the Compound
Drug 1 ( Fluphenazine )
| Drug Name | Fluphenazine | ||
|---|---|---|---|
| Company | Bristol-Myers Squibb | ||
| Indication | |||
| Target(s) | |||